King syndrome: what’s in a name?

References

[1] King MC."The race" to clone BRCA1.Science2014;343:1462-5

[2] Petrucelli N,Feldman G.Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2.Genet Med2010;12:245-59.

[3] Suther S.Barriers to the use of genetic testing: a study of racial and ethnic disparities.Genet Med2009;11:655-62

[4] Childers KK,Macinko J.National Distribution of Cancer Genetic Testing in the United States: Evidence for a Gender Disparity in Hereditary Breast and Ovarian Cancer.JAMA Oncol2018;4:876-9 PMCID:PMC6145682

[5] National Comprehensive Cancer Network Guidelines (2020). Genetic/Familial High-Risk Assessment Breast and Ovarian, Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf [Last accessed on 23 Mar 2021]

[6] Pritchard CC,Walsh MF.Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.N Engl J Med2016;375:443-53 PMCID:PMC4986616

[7] Mateo J,Sandhu S.DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.N Engl J Med2015;373:1697-708 PMCID:PMC5228595

[8] Lord CJ.PARP inhibitors: Synthetic lethality in the clinic.Science2017;355:1152-8 PMCID:PMC6175050

[9] CR, Lynch, HT. The history of Lynch syndrome.FAM CANCER2013;12:145-57

[10] Zhao P,Jiang X.Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.J Hematol Oncol2019;12:54 PMCID:PMC6544911

[11] Aebi S,Gordon R.Loss of DNA mismatch repair in acquired resistance to cisplatin.Cancer Res1996;56:3087-90

[12] Arnold CN,Boland CR.Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.Int J Cancer2003;106:66-73

[13] Carethers JM,Fink D.Mismatch repair proficiency and in vitro response to 5-fluorouracil.Gastroenterology1999;117:123-31 PMCID:PMC4343206

[14] Fink D,Aebi S.The role of DNA mismatch repair in platinum drug resistance.Cancer Res1996;56:4881-6